Role of PET/CT in the functional imaging of endocrine pancreatic tumors.

Détails

ID Serval
serval:BIB_2FBF79730494
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Role of PET/CT in the functional imaging of endocrine pancreatic tumors.
Périodique
Abdominal imaging
Auteur⸱e⸱s
Rufini V., Baum R.P., Castaldi P., Treglia G., De Gaetano A.M., Carreras C., Kaemmerer D., Hommann M., Hörsch D., Bonomo L., Giordano A.
ISSN
1432-0509 (Electronic)
ISSN-L
0942-8925
Statut éditorial
Publié
Date de publication
12/2012
Peer-reviewed
Oui
Volume
37
Numéro
6
Pages
1004-1020
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Endocrine pancreatic tumors (EPTs) are a heterogeneous group of neoplasms with variable clinical and biological features and prognosis, ranging from very slow-growing tumors to highly aggressive and very malignant ones. As other neuroendocrine tumors, EPTs are characterized by the presence of neuroamine uptake mechanisms and/or peptide receptors at the cell membrane and these features constitute the basis of the clinical use of specific radiolabeled ligands, both for imaging and therapy. The more widespread use of hybrid machines, i.e., positron emission tomography/computed tomography (PET/CT), allows to perform imaging with high resolution and high diagnostic accuracy especially for small lesions, and to correlate anatomic location with function. The recent WHO recommendations for classification and prognostic factors help the selection of tracers likely to show a positive image on PET; therefore, tracers exploiting specific metabolic patterns ((18)F-DOPA and (11)C-5-HTP) or specific receptor expression ((68)Ga-DOTA-peptides) are suited to well-differentiated tumors, while the use of (18)F-FDG is preferred for poorly-differentiated neoplasms with high proliferative activity and loss of neuroendocrine features. In differentiated EPTs, (11)C-5-HTP performs better than (18)F-DOPA even though its use is hampered by its complex production and limited availability and experience; (68)Ga-peptides are indicated for all type of gastroenteropancreatic (GEP) neuroendocrine tumors, regardless of their functional activity. In addition, (68)Ga-DOTA-peptides play a distinctive role in planning peptide receptor radionuclide therapy.

Mots-clé
Cell Differentiation, Contrast Media, Dopamine Agents/metabolism, Heterocyclic Compounds, Humans, Levodopa/metabolism, Multimodal Imaging, Neoplasm Metastasis/diagnostic imaging, Neoplasm Staging, Neuroendocrine Tumors/classification, Neuroendocrine Tumors/diagnostic imaging, Neuroendocrine Tumors/pathology, Neuroendocrine Tumors/secretion, Organometallic Compounds, Pancreatic Neoplasms/classification, Pancreatic Neoplasms/diagnostic imaging, Pancreatic Neoplasms/pathology, Pancreatic Neoplasms/secretion, Peptide Hormones/secretion, Positron-Emission Tomography, Prognosis, Radiopharmaceuticals, Tomography, X-Ray Computed
Pubmed
Web of science
Création de la notice
20/08/2017 21:04
Dernière modification de la notice
20/08/2019 13:14
Données d'usage